Novartis lines up Merck exec to replace R&D leader Jay Bradn...

Jay Bradner, president of the Novartis Institutes for Biomedical Research (NIBR), is retiring from the position after seven years in the role, and will be replaced by Merck & Co R&D

Novartis pulls rival to Roche’s risdiplam in SMA, says marke...

Jay Bradner: leading Novartis into age of digitally-enabled ...

Jay Bradner, head of Novartis’ drug discovery, talks to pharmaphorum about the firm’s drive to transform itself into 'a medicine and data science company'.